(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Investigating Remarkable Espresso Flavors: Upgrade Your Day to day Blend - 2Safeguarding Your Senior Protection Against Extortion and Tricks.
- 3The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- 4The most effective method to Oversee Unsold SUVs in the Car Business
- 5Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- New dietary guidelines recommend more dairy, meat and fats: What to know
- Pick Your Favored kind of sandwich
- Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- Solar storms can trigger auroras on Earth. This star’s explosion could destroy a planet’s atmosphere
- the 6 Shrewd Beds for seniors: A Complete Survey
- U.S. overhauls childhood vaccine schedule, recommends fewer shots
- AfD in Brandenburg takes back suit against the intelligence service
